$PDSB
PDS Biotechnology Corp

2023 Q2 Form 10-Q Financial Statement

#000114036123024692 Filed on May 15, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.691M $3.579M $3.318M
YoY Change 40.84% 7.86% 102.31%
% of Gross Profit
Research & Development $8.005M $5.844M $5.161M
YoY Change 112.8% 13.22% 265.26%
% of Gross Profit
Depreciation & Amortization $14.41K $3.155K $90.00
YoY Change 3405.56% -95.16%
% of Gross Profit
Operating Expenses $12.70M $9.422M $8.479M
YoY Change 79.0% 11.12% 178.07%
Operating Profit -$12.70M -$9.422M -$8.479M
YoY Change 79.0% 11.12% 178.07%
Interest Expense $995.4K $966.8K $5.700K
YoY Change 1235.21% 16862.19%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$12.94M -$9.660M -$8.474M
YoY Change 84.39% 14.0% 177.82%
Income Tax -$1.406M $0.00
% Of Pretax Income
Net Earnings -$11.53M -$9.660M -$8.474M
YoY Change 98.22% 14.0% 177.95%
Net Earnings / Revenue
Basic Earnings Per Share -$0.37 -$0.32 -$0.32
Diluted Earnings Per Share -$0.37 -$0.32 -$0.32
COMMON SHARES
Basic Shares Outstanding 30.82M 30.72M 26.16M
Diluted Shares Outstanding 30.80M 30.43M 26.16M

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $60.62M $65.20M $58.88M
YoY Change 14.42% 10.73% 135.52%
Cash & Equivalents $60.60M $65.20M $58.88M
Short-Term Investments
Other Short-Term Assets $2.726M $2.774M $1.849M
YoY Change -1.16% 49.99% -15.94%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $63.35M $67.97M $60.73M
YoY Change 13.65% 11.93% 122.81%
LONG-TERM ASSETS
Property, Plant & Equipment $143.6K $148.3K $308.3K
YoY Change -51.89% 8505.36%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $403.3K $475.3K $308.3K
YoY Change 56.2% 54.14% -38.92%
TOTAL ASSETS
Total Short-Term Assets $63.35M $67.97M $60.73M
Total Long-Term Assets $403.3K $475.3K $308.3K
Total Assets $63.75M $68.45M $61.04M
YoY Change 13.85% 12.14% 119.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.415M $2.072M $2.746M
YoY Change 135.09% -24.53% 188.84%
Accrued Expenses $3.376M $1.858M $2.273M
YoY Change 46.61% -18.23% 22.54%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $53.31K $52.11K
YoY Change
Total Short-Term Liabilities $7.904M $4.130M $5.018M
YoY Change 75.03% -17.71% 71.34%
LONG-TERM LIABILITIES
Long-Term Debt $23.41M $23.31M $0.00
YoY Change
Other Long-Term Liabilities $147.0K
YoY Change -70.6%
Total Long-Term Liabilities $23.41M $23.31M $147.0K
YoY Change 39138.68% 15758.03% -70.6%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.904M $4.130M $5.018M
Total Long-Term Liabilities $23.41M $23.31M $147.0K
Total Liabilities $31.31M $27.44M $5.165M
YoY Change 584.29% 431.17% 52.49%
SHAREHOLDERS EQUITY
Retained Earnings -$122.8M -$111.2M
YoY Change 63.68%
Common Stock $10.19K $10.14K
YoY Change 8.49%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $32.44M $41.01M $55.87M
YoY Change
Total Liabilities & Shareholders Equity $63.75M $68.45M $61.04M
YoY Change 13.85% 12.14% 119.87%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$11.53M -$9.660M -$8.474M
YoY Change 98.22% 14.0% 177.95%
Depreciation, Depletion And Amortization $14.41K $3.155K $90.00
YoY Change 3405.56% -95.16%
Cash From Operating Activities -$4.814M -$13.19M -$6.369M
YoY Change -18.66% 107.08% 67.51%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 240.0K 4.568M 7.490K
YoY Change 970.0% 60886.05%
NET CHANGE
Cash From Operating Activities -4.814M -13.19M -6.369M
Cash From Investing Activities
Cash From Financing Activities 240.0K 4.568M 7.490K
Net Change In Cash -4.574M -8.621M -6.362M
YoY Change -22.42% 35.51% 67.31%
FREE CASH FLOW
Cash From Operating Activities -$4.814M -$13.19M -$6.369M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
852774
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1436306
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
65200000
CY2022Q2 pdsb Proceeds From Sale Of Unused Net Operating Loss Carryforwards
ProceedsFromSaleOfUnusedNetOperatingLossCarryforwards
1200000
CY2022Q3 pdsb Shelf Registration Statement Available For Future Sale
ShelfRegistrationStatementAvailableForFutureSale
150000000
CY2022Q3 pdsb Placement Shares Available For Future Sale
PlacementSharesAvailableForFutureSale
50000000
CY2022Q3 pdsb Placement Shares Available For Future Sale
PlacementSharesAvailableForFutureSale
50000000
CY2022Q3 pdsb Commission Percentage
CommissionPercentage
0.03
CY2023Q1 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
11200
CY2023Q1 us-gaap Lessor Operating Lease Term Of Contract
LessorOperatingLeaseTermOfContract
P40M
CY2023Q1 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P5M
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
700000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
0
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
0
CY2023Q1 pdsb Lessee Operating Lease Liability To Be Paid Year Four And Thereafter
LesseeOperatingLeaseLiabilityToBePaidYearFourAndThereafter
0
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
150367
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
3387
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
146980
CY2022Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
1837330
CY2023Q1 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
69850
CY2023Q1 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
69850
CY2023Q1 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
40108
CY2023Q1 pdsb Finance Lease Liability To Be Paid Year Four And Thereafter
FinanceLeaseLiabilityToBePaidYearFourAndThereafter
26724
CY2023Q1 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
258920
CY2023Q1 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
41520
CY2023Q1 us-gaap Finance Lease Liability
FinanceLeaseLiability
217400
CY2023Q1 pdsb Lessee Finance Lease Number Of Leases
LesseeFinanceLeaseNumberOfLeases
4
CY2023Q1 pdsb Finance Lease Cost
FinanceLeaseCost
251959
CY2023Q1 us-gaap Lessee Finance Lease Discount Rate
LesseeFinanceLeaseDiscountRate
0.0915
CY2023Q1 pdsb Lessee Finance Lease Monthly Rental Expense
LesseeFinanceLeaseMonthlyRentalExpense
6000
CY2023Q1 pdsb Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
217779
CY2022Q4 pdsb Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
5645737
CY2023Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
563006
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
550259
CY2023Q1 us-gaap Accrued Rent Current
AccruedRentCurrent
3343
CY2022Q4 us-gaap Accrued Rent Current
AccruedRentCurrent
0
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1858391
CY2023Q1 pdsb Liability For Uncertain Tax Positions
LiabilityForUncertainTaxPositions
0
CY2022Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2023Q1 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2022Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
381625
CY2022Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
3.6685
CY2023Q1 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P10Y
CY2023Q1 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
449329
CY2023Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
2794659
CY2023Q1 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
94907
CY2022Q1 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
48957
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001472091
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5843686
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5161315
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3578728
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3317907
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
9422414
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
8479222
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-9422414
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-8479222
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
729341
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
5700
CY2023Q1 us-gaap Interest Expense
InterestExpense
966845
CY2022Q1 us-gaap Interest Expense
InterestExpense
0
CY2023Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-237504
CY2022Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
5700
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-9659918
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9659918
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-8473522
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8473522
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.32
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.32
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.32
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.32
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30428053
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30428053
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26161156
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26161156
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7488
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-6455317
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-226236
CY2020Q2 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.0915
CY2022 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
1238491
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9900000
CY2023Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
553293
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4600000
CY2020Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
700000
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
89102
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
43046
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
150367
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
0
CY2023Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
20667
CY2022Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
0
CY2023Q1 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
52388
CY2023Q1 us-gaap Property Plant And Equipment Additions
PropertyPlantAndEquipmentAdditions
151490
CY2023Q1 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
782075
CY2023Q1 us-gaap Interest Payable Current
InterestPayableCurrent
292188
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
280382
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8313708
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.4202
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.9913
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0406
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.011
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y29D
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y7M20D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
10.79
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.88
CY2023Q1 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2023Q1 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
0
CY2023Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
66000
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
55500
CY2023Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
961753
CY2023Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
121997

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0001140361-23-024692-index-headers.html Edgar Link pending
0001140361-23-024692-index.html Edgar Link pending
0001140361-23-024692.txt Edgar Link pending
0001140361-23-024692-xbrl.zip Edgar Link pending
brhc20052917_10q.htm Edgar Link pending
brhc20052917_ex31-1.htm Edgar Link pending
brhc20052917_ex31-2.htm Edgar Link pending
brhc20052917_ex32-1.htm Edgar Link pending
brhc20052917_ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image01.jpg Edgar Link pending
image02.jpg Edgar Link pending
image03.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
pdsb-20230331.xsd Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
pdsb-20230331_cal.xml Edgar Link unprocessable
pdsb-20230331_def.xml Edgar Link unprocessable
pdsb-20230331_lab.xml Edgar Link unprocessable
pdsb-20230331_pre.xml Edgar Link unprocessable
brhc20052917_10q_htm.xml Edgar Link completed
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending